Blueprint Medicines Corp

Blueprint Medicines — AAAAI 2023 Annual Meeting

35 slides from Blueprint Medicines's conference presentation, Feb 27, 2023

  1. Slide 1: Detailed data from registrational PIONEER study demonstrate broad impact of AYVAKIT in ISM

    Slide 1: Detailed data from registrational PIONEER study demonstrate broad impact of AYVAKIT in ISM

    AAAAI 2023 ANNUAL MEETING Not for promotional use © 2023 Blueprint Medicines Corporation Suki patient with indolent systemic mastocytosis Detailed data from registrational PIONEER study demonstrate broad impact of AYVAKIT in patients with ISM AAAAI 2023 Annual Meeting February 27, 2023

  2. Slide 2: Agenda

    Slide 2: Agenda

    AAAAI 2023 ANNUAL MEETING Not for promotional use 2 Agenda INTRODUCTION Kate Haviland, Chief Executive Officer, Blueprint Medicines PIONEER TRIAL RESULTS Mariana Castells, MD, PhD, Director, Mastocytosis Center, Brigham and Women’s Hospital DISCUSSION Becker Hewes, MD, Chief Medical Officer, Bluepri

  3. Slide 3: Forward-looking statements

    Slide 3: Forward-looking statements

    AAAAI 2023 ANNUAL MEETING Not for promotional use 3 Forward - looking statements This presentation contains forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 , as amended, including, without limitation, statements regarding plans, strategies, tim

  4. Slide 4: Introduction

    Slide 4: Introduction

    AAAAI 2023 ANNUAL MEETING Not for promotional use INTRODUCTION CHIEF EXECUTIVE OFFICER BLUEPRINT MEDICINES KATE HAVILAND

  5. Slide 5: AYVAKIT achieved the primary and all key secondary endpoints

    Slide 5: AYVAKIT achieved the primary and all key secondary endpoints

    AAAAI 2023 ANNUAL MEETING Not for promotional use 5 AYVAKIT achieved the primary and all key secondary endpoints TSS, total symptom score; VAF, variant allele fraction; MC, mast cell. Primary Endpoint Mean Change in TSS 0.003 Secondary Endpoints ≥30% Reduction in TSS 0.009 ≥50% Reduction in TSS 0.00

  6. Slide 6: Clinically meaningful impact across diversity of measures

    Slide 6: Clinically meaningful impact across diversity of measures

    AAAAI 2023 ANNUAL MEETING Not for promotional use 6 Clinically meaningful impact across diversity of measures IMPROVED SYMPTOMS WITH DEEPENED RESPONSES OVER TIME 2 IMPROVED QUALITY - OF - LIFE 3 AYVAKIT showed systemic impact with a safety profile supportive of chronic treatment RAPID AND SUSTAINED

  7. Slide 7: Blueprint is the leader in SM, with AYVAKIT anchoring our franchise

    Slide 7: Blueprint is the leader in SM, with AYVAKIT anchoring our franchise

    AAAAI 2023 ANNUAL MEETING Not for promotional use 7 Blueprint is the leader in SM, with AYVAKIT anchoring our franchise GLOBAL COMMERCIAL INFRASTRUCTURE • $111M in global AYVAKIT net sales in 2022, representing 2x YoY growth • ~500 U.S. patients on therapy • ~400 U.S. accounts with experience • Ongo

  8. Slide 8: Blueprint 2027: Doubling our impact, in half the time

    Slide 8: Blueprint 2027: Doubling our impact, in half the time

    AAAAI 2023 ANNUAL MEETING Not for promotional use 8 Blueprint 2027: Doubling our impact, in half the time Approved medicines Disease leadership areas Late - stage clinical programs Research platforms Cumulative development candidates 2011 - 2022 2 1 2 1 14 Planned 2022 - 2027 4+ 3+ 4+ 2 25+ 2027

  9. Slide 9: PIONEER Results

    Slide 9: PIONEER Results

    AAAAI 2023 ANNUAL MEETING Not for promotional use PIONEER RESULTS DIRECTOR, MASTOCYTOSIS CENTER BRIGHAM AND WOMEN’S HOSPITAL DR. MARIANA CASTELLS, MD, PHD

  10. Slide 10: Dr. Mariana Castells, MD, PhD

    Slide 10: Dr. Mariana Castells, MD, PhD

    AAAAI 2023 ANNUAL MEETING Not for promotional use Dr. Mariana Castells, MD, PhD AAAAI, American Academy of Allergy, Asthma & Immunology; ABAI, American Board of Allergy and Immunology. 10 • Brigham and Women’s Hospital, Boston ‒ Director, Mastocytosis Center ‒ Director, Drug Hypersensitivity and Des

  11. Slide 11: Efficacy and Safety of Avapritinib in ISM: Results from the PIONEER Study

    Slide 11: Efficacy and Safety of Avapritinib in ISM: Results from the PIONEER Study

    Efficacy and Safety of Avapritinib in Indolent Systemic Mastocytosis (ISM): Results from the Double - Blind Placebo - Controlled PIONEER Study AAAAI Annual Meeting, San Antonio, TX; February 24 – 27, 2023 Mariana Castells , 1* Jason Gotlib, 2* Hanneke Oude Elberink, 3 Frank Siebenhaar, 4,5 Karin Har

  12. Slide 12: ISM is a clonal mast cell disease driven by the KIT D816V mutation

    Slide 12: ISM is a clonal mast cell disease driven by the KIT D816V mutation

    Indolent systemic m astocytosis (ISM) is a clonal mast cell disease driven by the KIT D816V mutation in ~ 95% of adult cases 1 – 3 BSC, best supportive care; ISM, indolent systemic mastocytosis. Brain fog, depression, migraines, anxiety Bone/muscle pain, osteoporosis/ osteosclerosis Syncope, dizzine

  13. Slide 13: Avapritinib is a potent and highly selective oral therapy targeting KIT D816V

    Slide 13: Avapritinib is a potent and highly selective oral therapy targeting KIT D816V

    Avapritinib is a potent and highly selective oral therapy targeting KIT D816V, the underlying driver of systemic mastocytosis nM, nanomolar concentration. Avapritinib kinase inhibitor activity Highly selective kinome profile KIT D816V IC 50 =0.27 nM Potently and selectively inhibits the autophosphor

  14. Slide 14: Avapritinib in advanced systemic mastocytosis

    Slide 14: Avapritinib in advanced systemic mastocytosis

    Avapritinib in advanced systemic mastocytosis a Patients with systemic mastocytosis and an associated hematologic neoplasm only. b Data for best available therapy from retrospective real - world patient chart review, methodology described previously; shading represents 95% confidence interval. 17 Ad

  15. Slide 15: Registrational PIONEER study design

    Slide 15: Registrational PIONEER study design

    Registrational PIONEER study: Randomized, double - blind, placebo - controlled study in patients with ISM a The recommended dose of avapritinib for the double - blind period and open - label extension was identified based on efficacy and safety results from Part 1 that included 4 cohorts: 25 mg avap

  16. Slide 16: ISM-SAF: Validated symptom assessment tool

    Slide 16: ISM-SAF: Validated symptom assessment tool

    ISM - SAF: Validated symptom assessment tool specifically developed for evaluation of ISM symptomology 18 – 20 ISM Symptom Assessment Form (ISM - SAF) ISM Symptom Scoring Abdominal pain Scored 0 – 10 daily on handheld device 0 = no symptom 10 = worst imaginable symptom Analyzed as a 14 - day moving

  17. Slide 17: Baseline patient and disease characteristics were balanced between groups

    Slide 17: Baseline patient and disease characteristics were balanced between groups

    Baseline patient and disease characteristics were balanced between groups a The limit of detection was 0.02%. b Cytoreductive therapies included dasatinib, imatinib, masitinib, nilotinib, midostaurin, brentuximab vedotin, cladribine, hyd rox yurea, rapamycin, and interferon alfa. I ncludes treatment

  18. Slide 18: Rapid and sustained reductions in biomarkers of mast cell burden

    Slide 18: Rapid and sustained reductions in biomarkers of mast cell burden

    Rapid and sustained reductions in biomarkers of mast cell burden in avapritinib - treated patients versus placebo BM, bone marrow; CI, confidence interval. Patients with ≥ 50% reduction in peripheral blood KIT D816V VAF Baseline 4 8 12 16 20 24 ≥50% reduction or undetected KIT D816V (%) 118 63 110 5

  19. Slide 19: Significant and durable improvement in symptoms versus placebo

    Slide 19: Significant and durable improvement in symptoms versus placebo

    Avapritinib demonstrated significant and durable improvement in symptoms versus placebo SE, standard error of the mean. Visit (week) Mean change ± SE Roll over to open - label extension Double - blind treatment period Open - label extension Number of patients 139 71 137 71 135 71 135 68 137 67 136 6

  20. Slide 20: Improvement in all individual ISM symptoms versus placebo

    Slide 20: Improvement in all individual ISM symptoms versus placebo

    - 1.80 - 2.21 - 1.86 - 1.54 - 1.11 - 1.09 - 1.40 - 1.29 - 1.34 - 1.35 - 1.72 - 2.22 - 0.96 - 1.06 - 0.63 - 1.20 - 0.89 - 1.05 - 0.98 - 0.93 - 0.89 - 0.82 - 1.11 - 1.42 -3.0 -2.5 -2.0 -1.5 -1.0 -0.5 0.0 Mean TSS absolute change from baseline to 24 weeks, individual ISM - SAF, by treatment group Avapr

  21. Slide 21: Continued improvement in all individual symptoms at 48 weeks

    Slide 21: Continued improvement in all individual symptoms at 48 weeks

    - 1.80 - 2.21 - 1.86 - 1.54 - 1.11 - 1.09 - 1.40 - 1.29 - 1.34 - 1.35 - 1.72 - 2.22 - 0.96 - 1.06 - 0.63 - 1.20 - 0.89 - 1.05 - 0.98 - 0.93 - 0.89 - 0.82 - 1.11 - 1.42 - 2.33 - 2.79 - 2.65 - 1.92 - 1.51 - 1.36 - 1.43 - 1.79 - 1.48 - 1.58 - 1.88 - 2.31 -3.0 -2.5 -2.0 -1.5 -1.0 -0.5 0.0 Avapritinib 25

  22. Slide 22: ≥30% and ≥50% reduction in TSS over time

    Slide 22: ≥30% and ≥50% reduction in TSS over time

    ≥ 30% reduction in ISM - SAF TSS score over time ≥ 50% reduction in ISM - SAF TSS score over time Avapritinib - treated patients were significantly more likely than placebo to reach the TSS ≥30% and TSS ≥50% reduction thresholds over time Placebo Placebo group crossing over to receive avapritinib 25

  23. Slide 23: Sustained improvement in MC-QoL versus placebo

    Slide 23: Sustained improvement in MC-QoL versus placebo

    Avapritinib demonstrated sustained improvement in MC - QoL versus placebo, an established and validated disease - specific QoL measure ITT, intent - to - treat. *p≤0.05. - 28.41 * - 38.52 * - 41.47 * - 24.11 - 14.58 - 16.58 - 23.44 - 11.98 % Change from baseline 20 25 30 35 40 45 50 55 60 65 70 Chan

  24. Slide 24: Avapritinib 25mg QD well tolerated, similar safety profile to placebo

    Slide 24: Avapritinib 25mg QD well tolerated, similar safety profile to placebo

    Avapritinib 25mg QD was well tolerated, with a similar safety profile to placebo Avapritinib 25 mg QD (N=141) Placebo (N=71) Any AEs a,b , n (%) 128 (90.8) 66 (93.0) Grade 1 – 2 AEs 98 (69.5) 51 (71.8) Grade 1 – 2 related AEs 74 (52.5) 30 (42.3) Grade ≥3 AEs 30 (21.3) 15 (21.1) Grade ≥3 related AEs

  25. Slide 25: Summary

    Slide 25: Summary

    Summary • ISM patients can suffer from a wide range of debilitating symptoms often not adequately controlled by BSC medications • PIONEER is the first randomized, double - blind, placebo - controlled trial of a highly selective KIT D816V - targeting agent in patients with Indolent SM • Avapritinib -

  26. Slide 26: Acknowledgements

    Slide 26: Acknowledgements

    Acknowledgements • We thank the patients and their families for making this trial possible • We also thank the investigators and clinical trial teams who participated in the trial • Medical writing support was provided by Will Wheddon, MSci, and editorial support was provided by Travis Taylor, BA, a

  27. Slide 27: Discussion

    Slide 27: Discussion

    Not for promotional use DISCUSSION CHIEF MEDICAL OFFICER BLUEPRINT MEDICINES BECKER HEWES, MD

  28. Slide 28: PIONEER trial population is representative of the real world

    Slide 28: PIONEER trial population is representative of the real world

    AAAAI 2023 ANNUAL MEETING Not for promotional use 28 PIONEER trial population is representative of the real world 1. Claims algorithm considers number & type of SM diagnosis codes, comorbidities including associated hematologic neoplasms ( AHN s) and evidence of organ damage (e.g., splenomegaly, hep

  29. Slide 29: AYVAKIT showed consistent impact on all symptoms measured by the ISM-SAF

    Slide 29: AYVAKIT showed consistent impact on all symptoms measured by the ISM-SAF

    AAAAI 2023 ANNUAL MEETING Not for promotional use 29 AYVAKIT showed consistent impact on all symptoms measured by the ISM - SAF 1. Blueprint Medicines PIONEER data 0.0 1.5 3.0 4.5 6.0 7.5 Flushing Itching Spots Brain Fog Dizziness Headache Bone Pain Fatigue Abdominal Pain Diarrhea Severity Nausea Me

  30. Slide 30: Rapid and sustained improvement on individual symptoms

    Slide 30: Rapid and sustained improvement on individual symptoms

    AAAAI 2023 ANNUAL MEETING Not for promotional use 30 AYVAKIT showed rapid and sustained improvement on individual symptoms 1. Blueprint Medicines PIONEER data -50 -40 -30 -20 -10 0 10 Baseline Week 4 Week 8 Week 12 Week 16 Week 20 Week 24 Baseline Week 4 Week 8 Week 12 Week 16 Week 20 Week 24 Percen

  31. Slide 31: AYVAKIT induced responses that deepened over time

    Slide 31: AYVAKIT induced responses that deepened over time

    AAAAI 2023 ANNUAL MEETING Not for promotional use 31 AYVAKIT induced responses in patients that deepened over time 1. Blueprint Medicines PIONEER data MEAN CHANGE IN TSS FOR AYVAKIT PATIENTS 61% 39% % with ≥30% TSS reduction at 48 weeks % with ≥50% TSS reduction at 48 weeks

  32. Slide 32: Consistent impact on quality-of-life measures at 24 weeks

    Slide 32: Consistent impact on quality-of-life measures at 24 weeks

    AAAAI 2023 ANNUAL MEETING Not for promotional use 32 AYVAKIT demonstrated consistent impact on quality - of - life measures at 24 weeks 1. Blueprint Medicines PIONEER data Disease - specific QoL measure General QoL and health status measures 20.0% 12.3% 18.5% - 25.8% - 34.3% 12.1% 6.3% 4.5% - 6.8% -

  33. Slide 33: Open-label PIONEER part will continue to generate important data

    Slide 33: Open-label PIONEER part will continue to generate important data

    AAAAI 2023 ANNUAL MEETING Not for promotional use 33 Open - label PIONEER part 3 will continue to generate important data on AYVAKIT 1. Blueprint Medicines PIONEER data Randomized PIONEER part 2 was not designed to assess polypharmacy reduction, however changes observed in patients treated with AYVA

  34. Slide 34: Blueprint is the leader in SM, with AYVAKIT anchoring our franchise

    Slide 34: Blueprint is the leader in SM, with AYVAKIT anchoring our franchise

    AAAAI 2023 ANNUAL MEETING Not for promotional use 34 Blueprint is the leader in SM, with AYVAKIT anchoring our franchise Statistically significant and clinically meaningful PIONEER data debuted at premiere allergy/immunology conference US and EMA regulatory submissions accepted May 22 US PDUFA date

  35. Slide 35: Q&A

    Slide 35: Q&A

    AAAAI 2023 ANNUAL MEETING Not for promotional use Q&A

Source: SEC EDGAR · 8-K filed Feb 27, 2023

More decks from Blueprint Medicines Corp